How long can Selpercatinib be used for drug resistance?

Selpercatinib is an inhibitor that targets the RET fusion gene. It is mainly used to treat malignant tumors such as non-small cell lung cancer (NSCLC) and thyroid cancer related to RET gene changes. As a precisely targeted drug, seputinib can effectively inhibit the growth and spread of tumor cells and significantly delay disease progression. However, like many targeted therapies, patients may gradually develop drug resistance during treatment with seputinib, resulting in a weakening of the drug's efficacy.

Regarding the resistance time to seputinib, current clinical studies show that patients’ response time to this drug varies greatly, usually ranging from months to years. Some patients can maintain treatment effects for a long time and may be resistant for more than two years, while others may experience disease progression within a year of treatment. The length of drug resistance is affected by many factors, including the biological characteristics of the tumor, the patient's genetic mutation status, and whether it is combined with other treatments.

After resistance to seputinib, clinical treatment options may need to be adjusted, such as replacing other targeted drugs, combining chemotherapy or immunotherapy, to delay disease progression. Doctors usually monitor patients' treatment response and drug resistance through regular imaging examinations and genetic testing, and adjust treatment strategies in a timely manner to ensure that patients get the best results.

In general, the resistance time to seputinib varies from person to person and can reach up to several years, but most patients will develop resistance within one to two years. Continuous clinical research and new drug development are working to extend the progression-free survival of patients, improve the overall treatment effect, and bring more treatment hope to patients with RET gene-related cancers.

Reference materials:https://en.wikipedia.org/wiki/Selpercatinib